First-line systemic therapy trials for advanced transitional-cell carcinoma of the urothelium: should we stop separating cisplatin-eligible and -ineligible patients?

@article{Sonpavde2010FirstlineST,
  title={First-line systemic therapy trials for advanced transitional-cell carcinoma of the urothelium: should we stop separating cisplatin-eligible and -ineligible patients?},
  author={Guru P Sonpavde and Matthew David Galsky and Nicholas John Vogelzang},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2010},
  volume={28 25},
  pages={e441-2; author reply e443-4}
}
TO THE EDITOR: Patients with advanced transitional-cell carcinoma (TCC) of the urothelium have traditionally been studied in randomized trials designed for two separate populations: cisplatin eligible and cisplatin ineligible. For cisplatin-eligible patients, methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC), dose-dense (DD) M-VAC, or gemcitabine and cisplatin (GC) are all considered acceptable options. However, the median progression-free survival (PFS) and overall survival are… CONTINUE READING